Cancer remains a leading cause of death globally, accounting for nearly one in every six deaths and posing a severe threat to public health. Despite this, ongoing research into cancer treatment continues to yield promising new strategies and approaches aimed at improving cure rates.
A recent study has highlighted the potential of Gamma delta T cells, identifying them as the most prognostically beneficial immune cell subset within tumor infiltrates from 18,000 tumors across 39 malignancies. This positions γδ T-cells as a highly promising effector cell compartment for cancer immunotherapy. Currently, γδ T cells have demonstrated potent anti-tumor efficacy against various cancers, including breast cancer, colon cancer, lung cancer, and leukemia.
As innate immune cells, γδ T cells can recognize tumor cells independently of human leukocyte antigen (HLA) restriction and rapidly produce abundant cytokines and potent cytotoxicity in response to malignancies. Several favorable features make γδ T cells ideal candidates for T cell-based cancer therapy:
Broad Antigen Recognition: γδ T cells can recognize a wide range of antigens on various cancer cells.
MHC-Independent Recognition: They recognize their target cells independently of the major histocompatibility complex (MHC).
Tissue Distribution and Rapid Response: γδ T cells are distributed in various tissues and can quickly respond to target tumor cells.
Immune Cell Interaction: γδ T cells interact with other immune cells, such as B cells, to drive a cascade of immune responses against tumors.
Isolating and purifying functional and specific γδ T cell populations from complex biological samples is crucial for understanding their biological function and developing γδ T cell-based therapies. Outstanding technologies for T cell isolation are essential in this process. Magnetic bead cell sorting (MACS) is a frequent, efficient, and quick method for isolating uncontaminated γδ T lymphocytes from human peripheral blood mononuclear cells (PBMCs).
Moreover, given the critical role of γδ T cells in combating various diseases, testing their activity and cytotoxicity is essential. Common cytotoxicity tests include the LDH cytotoxicity test, flow cytometry-based cytotoxicity test, and impedance-based label-free real-time cytotoxicity assay, with the LDH cytotoxicity test being one of the most frequently used methods.
Creative Biolabs, a biotechnology company, focuses on leveraging the unique properties of γδ T cells to combat human cancers. They have established and optimized robust platforms for the selective isolation and expansion of anticancer γδ T cell populations from human tissues. Additionally, they offer preclinical research services to assess the safety and efficacy of γδ T cell-based cancer immunotherapy.
Through their innovative work, Creative Biolabs provides hope for more effective and targeted cancer treatments, advancing the field of cancer immunotherapy and offering new possibilities for patients worldwide.
